Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,498.31
(
-1.42%
)
US TECH 100
23,024.40
(
-2.08%
)
Dow Jones
46,050.14
(
-0.82%
)
Brent Oil
101.99
(
3.25%
)
Bitcoin
68,327.75
(
-4.17%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122814
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bickema post# 199871

Tuesday, 02/23/2016 4:06:47 PM

Tuesday, February 23, 2016 4:06:47 PM

Post# of 257293
Hard to say—the end result may be the same.

Correction to my previous post in this thread: LLY may decide to sue EGRX when the FDA accepts EGRX's RTU-Alimta NDA for review and EGRX notifies LLY of a Paragraph-IV challenge (not when the FDA approves the product for marketing).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now